Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SSR591813L (dianicline)
SSR591813L · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| SSR591813L (dianicline) | DRUG | - |
Inclusion Criteria: * Outpatients, over legal age, smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit. Exclusion Criteria: * Patients who have taken an investigational drug within the past six months prior to the screening visit. * Patients who had a pr...
SSR591813L is an investigational small molecule developed by Sanofi as an aid to smoking cessation in cigarette smokers. It is also known as dianicline. The compound was studied in a Phase 3 clinical trial in adults aged 18 years and older in the United States and Canada.
SSR591813L was developed as a treatment aid for smoking cessation in cigarette smokers. Its Phase 3 trial enrolled adults who wanted to stop smoking, and the study assessed efficacy and safety of dianicline for tobacco use cessation. It is not approved for any use and remains an investigational therapy.
SSR591813L is developed by Sanofi, which trades under the ticker SNY. Sanofi sponsored the Phase 3 AMERIDIAN trial of dianicline as an aid to smoking cessation. No other developer or partner is associated with the program based on the trial record.
SSR591813L reached Phase 3 clinical development. Its single Phase 3 trial, AMERIDIAN, has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for smoking cessation or any other indication.
SSR591813L was studied in one Phase 3 trial, NCT00387946, titled Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers, also called AMERIDIAN. The trial enrolled 630 participants, was randomized and double blind, and was conducted in the United States and Canada. It is now completed.
Yes, SSR591813L is also known as dianicline. The two names refer to the same Sanofi compound, and the Phase 3 smoking cessation trial NCT00387946 is listed under the dianicline name. Searches for either term point to the same investigational small molecule program.